Supplementary Materials

Supplementary Material for:

Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome

Rajendra Kedlaya, Shreya Veera, Daniel J. Horan, Rachel E. Moss, Ugur M. Ayturk, Christina M. Jacobsen, Margot E. Bowen, Chris Paszty, Matthew L. Warman, Alexander G. Robling*

*Corresponding author. E-mail: arobling@iupui.edu

Published 13 November 2013, Sci. Transl. Med. 5, 211ra158 (2013)
DOI: 10.1126/scitranslmed.3006627

This PDF file includes:

  • Fig. S1. Body mass in mutant Lrp5 and Sost female and male mice.
  • Fig. S2. Photomicrographs of MacNeal/von Kossa–stained sections from the distal femur of Sost/Lrp5 mutant male mice.
  • Fig. S3. Photomicrographs of MacNeal/von Kossa–stained sections from the distal femur of wild-type and Lrp5−/− mice that were treated for 3 weeks with vehicle (saline) or sclerostin antibody (Scl-AbIII).
  • Fig. S4. Photomicrographs of the growth plate and primary spongiosa (upper panels) and the cortex (lower panels) from the proximal tibia of 15-week-old wild-type and Sost−/− mice that were immunolabeled for p-Smad 1/5/8 (brown staining) and counterstained with hematoxylin (purple staining).

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Collection of genes whose expression is different by twofold or more (in either direction) after 2 weeks of Scl-AbIII treatment versus vehicle treatment in 10-week-old wild-type mice.

[Table S1]